- Regioselective addition of mesitol to a 2,4-dichloropyridine
-
The regioseleethity of the addition of 2,4,6-trimethylphenol to 2,4-dichloro-3,6-dimethylpyridine can be controlled by the proper choice of catalyst and solvent. The use of catalytic eopper(I) salts and pyridine as solvent results in exclusive addition at
- Ruggeri, Sally Gut,Vanderplas, Brian C.,Anderson, Bruce G.,Breitenbach, Ralph,Urban, Frank J.,Stewart III, A. Morgan,Young, Gregory R.
-
-
Read Online
- Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin-releasing factor 1 receptor antagonists
-
A series of 2-aryloxy-4-alkoxy-pyridines (1) was identified as novel, selective, and orally active antagonists of the corticotropin-releasing factor 1 (CRF1) receptor. Among these, compound 2 (CP-316311) is a potent and selective CRF1/sub
- Chen, Yuhpyng L.,Braselton, John,Forman, James,Gallaschun, Randall J.,Mansbach, Robert,Schmidt, Anne W.,Seeger, Thomas F.,Sprouse, Jeff S.,Tingley III, F. David,Winston, Elizabeth,Schulz, David W.
-
p. 1377 - 1384
(2008/09/20)
-
- Corticotropin releasing factor antagonists
-
Corticotropin-releasing factor (CRF) antagonists having the formulae wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the application, and processes fo
- -
-
-
- Use of CRF antagonists and renin-angiotensin system inhibitors
-
The present invention relates to compositions and methods of achieving a therapeutic effect including, but not limited to, the treatment of congestive heart failure or hypertension in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist and a renin-angiotensin system (RAS) inhibitor.
- -
-
-
- QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death
-
A method of preventing sudden death which comprises administering to a mammal, including a human, a therapeutically effective amount of a corticotropin releasing factor antagonist.
- -
-
-
- New uses for corticotropin releasing factor antagonists
-
A method of treating, preventing or inhibiting a disorder selected from the group consisting of cardiovascular or heart related diseases such as stroke, hypertension, tachycardia, and congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, and colonic hypersensitivity associated with psychopathological disturbance and stress, comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of the formula or pharmaceutically acceptable salt thereof, wherein A, B, D, E, Y, Z, R3, R4, and R5 are as defined herein.
- -
-
-
- Method of treating heart failure
-
This invention relates to method for treating a mammal which presents with heart failure comprising administering to a mammal a therapeutically effective amount of wherein 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine and (3,6-dime
- -
-
-
- CORTICOTROPIN RELEASING FACTOR ANTAGONISTS
-
Corticotropin-releasing factor (CRF) antagonists having formulae (I), (II) or (III) wherein the dashed lines, A, B, Y, Z, G, R. sub.3, R. sub.4, R. sub.5, R 6, R 16 and R 17 are as defined in the description, and processes for preparing them. These compou
- -
-
-
- Use of 3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridines for treating heart failure
-
This invention relates to treatments for a mammal which presents with heart failure comprising administering to a mammal a therapeutically effective amount of wherein 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine and (3,6-dimethyl-
- -
-
-